Core Viewpoint - The active equity funds have seen a steady increase in net asset value (NAV), with 228 funds reaching all-time highs as of June 25, driven by market trends and effective fund management [1][2]. Group 1: Fund Performance - As of June 25, 2023, the unit NAV of the Guangfa Technology Select Stock Fund, established on April 17, 2023, reached a new high of 1.0627 yuan, focusing on investment opportunities in technology-themed companies [1]. - The CITIC Prudential Prosperity Mixed Fund, launched in February 2024, achieved a unit NAV of 1.6317 yuan on June 25, with a focus on consumer sectors, industries benefiting from stable growth, national security, and high-tech manufacturing [2]. - The Jinyuan Shun'an Yuanqi Flexible Allocation Mixed Fund, established in November 2017, reached a unit NAV of 5.5162 yuan on June 25, with a three-year NAV growth rate of 78.24% [2]. - The Guangfa Multi-Factor Mixed Fund, launched in December 2016, achieved a unit NAV of 3.9408 yuan on June 25, with a three-year NAV growth rate of 14.59% [3]. Group 2: Market Trends and Insights - The continuous expansion of market hotspots and significant structural opportunities have supported the growth of fund NAVs, with sectors like technology, new energy, new consumption, and pharmaceuticals performing well since 2025 [1]. - The market is expected to maintain a technology-driven trend in 2025, with an overall increase in risk appetite as external disturbances ease, suggesting a focus on technology, consumption, high-end manufacturing, and pharmaceuticals [2]. - The performance of active equity funds has been challenging against benchmarks in recent years, but a longer evaluation period shows that some high-performing funds can outperform indices, highlighting the importance of fund managers' capabilities [3].

本报记者 王宁 QDII（合格境内机构投资者）基金年内净值表现出现分化态势。 据Wind资讯数据统计，截至5月26日，全市场310只QDII基金中，有45只产品年内净值增长率超过20%，其中排名首位的产 品净值增长率接近67%；与之相对应的是，有76只QDII基金年内净值出现回调，其中有11只产品净值回调超过8%。 《证券日报》记者梳理发现，净值增长率居前的QDII基金几乎均重仓了医药板块，而排名靠后的产品多为商品型基金，且 以油气类主题产品为主。在分析人士看来，年内医药板块确定性较强，向上行情为相关基金净值带来明显提振，而国际原油和 天然气等商品价格维持弱势，从而导致油气类主题产品净值出现回调，令QDII基金整体业绩分化明显。 与之相对应的净值回调的76只QDII基金中，华宝标普油气A人民币、富国标普石油天然气勘探及生产精选行业ETF、博时 标普石油天然气勘探及生产精选行业指数A、易方达原油A人民币等11只产品净值回调均超过8%。 通过对上述QDII基金进行分析，净值增长较强的产品基本重仓医药资产，而净值出现较明显回撤的产品多重仓商品资产。 业绩分化明显 数据显示，截至5月26日，全市场310只QDII基金 ...

截至2025年4月28日 11:06，中证港股通医药卫生综合指数(930965)下跌2.09%。成分股方面涨跌互现，心泰医疗(02291)领涨6.75%，国药控股(01099)上涨 3.79%，东阳光长江药业(01558)上涨2.62%；康方生物(09926)领跌13.09%，三生制药(01530)下跌11.06%，云顶新耀-B(01952)下跌5.91%。港股医药 ETF(159718)下跌2.09%，最新报价0.7元。拉长时间看，截至2025年4月25日，港股医药ETF近1周累计上涨6.99%。 份额方面，港股医药ETF近1周份额增长5500.00万份，实现显著增长，新增份额位居可比基金1/4。 资金流入方面，港股医药ETF近5个交易日内，合计"吸金"3793.13万元。 截至2025年4月28日 11:06，中证医药及医疗器械创新指数(931484)下跌0.52%。成分股方面涨跌互现，百利天恒(688506)领涨4.77%，奕瑞科技(688301)上涨 3.04%，新产业(300832)上涨1.64%；神州细胞(688520)领跌3.40%，智飞生物(300122)下跌2.92%，心脉医疗(688016 ...